India Said to Seek Review of U.S. Court Ruling Papers on Ranbaxy

India’s health ministry has asked the nation’s drug regulator to review U.S. court documents that alleged Ranbaxy Laboratories Ltd. sold adulterated drugs, according to a ministry official familiar with the matter.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.